These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 29992313)

  • 21. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives in weight control in diabetes - Survodutide.
    Klein T; Augustin R; Hennige AM
    Diabetes Res Clin Pract; 2024 Jan; 207():110779. PubMed ID: 37330144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.
    Franklin ZJ; Lafferty RA; Flatt PR; McShane LM; O'Harte FPM; Irwin N
    Biochimie; 2022 Aug; 199():60-67. PubMed ID: 35439540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
    Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
    Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
    Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
    Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.
    Vishnoi S; Bhattacharya S; Walsh EM; Okoh GI; Thompson D
    J Chem Inf Model; 2023 Aug; 63(15):4934-4947. PubMed ID: 37523325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
    He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
    PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
    Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
    EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice.
    Wei T; Cui X; Jiang Y; Wang K; Wang D; Li F; Lin X; Gu L; Yang K; Yang J; Hong T; Wei R
    Diabetes; 2023 May; 72(5):599-610. PubMed ID: 36826938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
    Gu W; Winters KA; Motani AS; Komorowski R; Zhang Y; Liu Q; Wu X; Rulifson IC; Sivits G; Graham M; Yan H; Wang P; Moore S; Meng T; Lindberg RA; Véniant MM
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E624-32. PubMed ID: 20647556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.
    Eriksson O; Haack T; Hijazi Y; Teichert L; Tavernier V; Laitinen I; Berglund JE; Antoni G; Velikyan I; Johansson L; Pierrou S; Wagner M; Tillner J
    Sci Rep; 2020 Oct; 10(1):16758. PubMed ID: 33028880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural analysis of the dual agonism at GLP-1R and GCGR.
    Li Y; Zhou Q; Dai A; Zhao F; Chang R; Ying T; Wu B; Yang D; Wang MW; Cong Z
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303696120. PubMed ID: 37549266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
    Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
    Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
    Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
    Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1.
    Liu Y; Zhou Y; Wang Y; Geng D; Liu J
    Obes Surg; 2011 Sep; 21(9):1424-31. PubMed ID: 21479766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.
    Chang R; Zhang X; Qiao A; Dai A; Belousoff MJ; Tan Q; Shao L; Zhong L; Lin G; Liang YL; Ma L; Han S; Yang D; Danev R; Wang MW; Wootten D; Wu B; Sexton PM
    J Biol Chem; 2020 Jul; 295(28):9313-9325. PubMed ID: 32371397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.
    Elfers CT; Chichura KS; Ashlaw EF; Chepurny OG; Holz GG; Doyle RP; Roth CL
    Clin Nutr; 2024 Jul; 43(7):1782-1790. PubMed ID: 38861891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
    Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
    Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.